Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen (Nasdaq: PGEN), a biopharmaceutical company focused on innovative gene and cell therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Helen Sabzevari, the company's President and CEO, will deliver a presentation on Thursday, January 16, 2025, at 9:00 AM PT in San Francisco, California.
The company specializes in developing next-generation gene and cell therapies using precision technology, targeting three core therapeutic areas: immuno-oncology, autoimmune disorders, and infectious diseases. Their approach focuses on creating affordable biotherapeutics through controlled innovation, with an active preclinical and clinical pipeline progressing toward clinical proof-of-concept and commercialization.
Precigen (Nasdaq: PGEN), una compagnia biofarmaceutica focalizzata su terapie innovative geniche e cellulari, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La Dott.ssa Helen Sabzevari, Presidente e CEO dell'azienda, presenterà il suo intervento giovedì 16 gennaio 2025, alle 9:00 AM PT a San Francisco, California.
L'azienda è specializzata nello sviluppo di terapie geniche e cellulari di nuova generazione utilizzando tecnologie di precisione, mirando a tre aree terapeutiche principali: immuno-oncologia, disturbi autoimmuni e malattie infettive. Il loro approccio si concentra sulla creazione di bioterapeutiche accessibili attraverso un'innovazione controllata, con un attivo pipeline preclinica e clinica in fase di progresso verso la prova di concetto clinico e commercializzazione.
Precigen (Nasdaq: PGEN), una compañía biofarmacéutica centrada en terapias innovadoras de gen y célula, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. La Dra. Helen Sabzevari, Presidenta y CEO de la empresa, dará una presentación el jueves 16 de enero de 2025, a las 9:00 AM PT en San Francisco, California.
La compañía se especializa en el desarrollo de terapias de gen y célula de nueva generación utilizando tecnología de precisión, enfocándose en tres áreas terapéuticas clave: inmuno-oncología, trastornos autoinmunes y enfermedades infecciosas. Su enfoque se centra en crear bioterapéuticas asequibles a través de una innovación controlada, con un pipeline preclínico y clínico activo avanzando hacia la prueba de concepto clínica y comercialización.
프레시겐 (Nasdaq: PGEN)은 혁신적인 유전자 및 세포 치료에 중점을 둔 생명공학 회사로, 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 헬렌 사브제바리 박사는 2025년 1월 16일 목요일, 오전 9:00 PT에 샌프란시스코, 캘리포니아에서 발표를 진행할 예정입니다.
회사는 정밀 기술을 사용하여 차세대 유전자 및 세포 치료제를 개발하는 전문 기업으로, 면역 종양학, 자가 면역 질환 및 감염병이라는 세 가지 핵심 치료 분야에 초점을 맞추고 있습니다. 그들의 접근 방식은 통제된 혁신을 통해 저렴한 생물 치료제를 만드는 데 중점을 두며, 임상 개념 증명 및 상용화에 따른 진행 중인 활성 전임상 및 임상 파이프라인을 보유하고 있습니다.
Precigen (Nasdaq: PGEN), une entreprise biopharmaceutique axée sur des thérapies géniques et cellulaires innovantes, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Dr. Helen Sabzevari, Présidente et CEO de l'entreprise, fera une présentation le jeudi 16 janvier 2025, à 9h00 PT à San Francisco, Californie.
L'entreprise se spécialise dans le développement de thérapies géniques et cellulaires de nouvelle génération utilisant une technologie de précision, ciblant trois domaines thérapeutiques clés : immuno-oncologie, maladies auto-immunes et maladies infectieuses. Leur approche se concentre sur la création de biothérapeutiques abordables grâce à une innovation contrôlée, avec un pipeline préclinique et clinique actif en cours de progression vers la preuve de concept clinique et la commercialisation.
Precigen (Nasdaq: PGEN), ein biopharmazeutisches Unternehmen, das sich auf innovative Gentherapien und Zelltherapien konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Dr. Helen Sabzevari, Präsidentin und CEO des Unternehmens, wird am Donnerstag, den 16. Januar 2025, um 9:00 Uhr PT in San Francisco, Kalifornien, eine Präsentation halten.
Das Unternehmen ist auf die Entwicklung von Gentherapien und Zelltherapien der nächsten Generation spezialisiert, die Präzisionstechnologie nutzen, und konzentriert sich auf drei zentrale Therapiegebiete: Immunonkologie, autoimmune Erkrankungen und Infektionskrankheiten. Ihr Ansatz konzentriert sich darauf, erschwingliche Biotherapeutika durch kontrollierte Innovation zu schaffen, mit einer aktiven präklinischen und klinischen Pipeline, die auf klinische Machbarkeitsstudien und Kommerzialisierung hinarbeitet.
- None.
- None.
Participants may view details for this event through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, regulatory approvals, commercial launches and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302346389.html
SOURCE Precigen, Inc.
FAQ
When and where will Precigen (PGEN) present at the J.P. Morgan Healthcare Conference 2025?
What are the main therapeutic areas Precigen (PGEN) focuses on?
How can investors access Precigen's (PGEN) J.P. Morgan Healthcare Conference presentation?
What is Precigen's (PGEN) approach to developing biotherapeutics?
Who will represent Precigen (PGEN) at the 2025 J.P. Morgan Healthcare Conference?
